3//SEC Filing
ARIAD PHARMACEUTICALS INC 3
Accession 0001395064-21-000201
CIK 0001745020operating
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 6:10 PM ET
Size
7.4 KB
Accession
0001395064-21-000201
Insider Transaction Report
Form 3
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Holdings
- (indirect: See explanation)
Series A Preferred Stock
→ Common Stock (1,615,427 underlying)
ARIAD PHARMACEUTICALS INC
10% Owner
Holdings
- (indirect: See explanation)
Series A Preferred Stock
→ Common Stock (1,615,427 underlying)
Footnotes (3)
- [F1]These shares of the Issuers Series A Preferred Stock are expected to convert on a one-for-one basis into the number of shares of the Issuers common stock, par value $0.0001 per share (Common Stock), shown in Column 3 immediately upon the closing of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock has no expiration date.
- [F2]This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.
- [F3]Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 1,615,427 shares of Series A Preferred Stock held by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Documents
Issuer
Theseus Pharmaceuticals, Inc.
CIK 0001745020
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000884731
Filing Metadata
- Form type
- 3
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 6:10 PM ET
- Size
- 7.4 KB